Novel Anti-Asporin Antibody Targets Fibrotic Disease Including Idiopathic Pulmonary Fibrosis
Summary
USPTO published patent application US20260098083A1 disclosing a novel antibody binding specifically to Asporin protein for predicting onset and treating fibrotic diseases, including idiopathic pulmonary fibrosis. Inventors are Hogeun Yoon and Soo-Yeon Park. The application was filed on September 20, 2023.
What changed
USPTO published patent application US20260098083A1 disclosing an anti-Asporin antibody for predicting and treating fibrotic diseases, including idiopathic pulmonary fibrosis. The invention provides an antibody that binds specifically to Asporin protein involved in fibrosis pathways, offering a diagnostic, preventive, and therapeutic approach where no clear pathogenic mechanism has been established.
For biotechnology and pharmaceutical companies, this patent represents a potential therapeutic target for fibrosis treatment. Researchers and drug developers should monitor this application's prosecution for claim scope and evaluate whether Asporin inhibition represents a viable pipeline opportunity. Patent examiners may cite this reference in related antibody or fibrosis therapy applications.
What to do next
- Monitor for patent grant or office action
- Evaluate licensing opportunities for Asporin-targeting antibody development
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Novel Antibody For Prevention Or Treatment Of Fibrotic Disease
Application US20260098083A1 Kind: A1 Apr 09, 2026
Inventors
Hogeun YOON, Soo-Yeon PARK
Abstract
The present invention relates to a method for prevention or treatment of fibrotic disease, wherein an antibody binding specifically to Asporin protein involved in fibrosis is used for predicting the onset of fibrotic disease or for inhibiting the activity of the corresponding protein. The present invention provides an effective antibody that can be used for the diagnosis, prevention, and treatment of idiopathic pulmonary fibrosis, a condition for which efficient treatment methods have been absent because a clear pathogenic mechanism is not known therefor. In addition, the present invention can be advantageously used to effectively block fibrosis in various tissues by ultimately providing a fundamental inhibitory method for pathological fibrosis mechanisms.
CPC Classifications
C07K 16/18 A61P 7/04 C07K 2317/76
Filing Date
2023-09-20
Application No.
19112732
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.